智通财经APP获悉，基石药业-B(02616)盘中涨超6%，截至发稿，涨6.36%，报5.69港元，成交额3944.46万港元。
消息面上，香港联交所资料显示，2025年12月23日，新加坡政府投资公司(GIC)增持基石药业90.45万股，总金额约为528.92万港元。增持后，GIC最新持股数目增至约1.19亿股，持股比例达8.06%。值得注意的是，自2025年8月18日GIC首次披露持有基石药业5.49%股份后，其加仓动作从未间断：10月13日、11月10日两度增持披露后，持股比例升至7.11%，直至本次披露的持股比例增至8.06%。
平安证券研报指出，基石药业以临床开发为引擎，研发1.0阶段商业化产品贡献可靠现金流量，研发2.0阶段项目创新布局研发管线及前沿技术，核心品种已迈入临床试验阶段且后续将持续推进候选项目进入临床，预计2025-2027年公司实现收入1.95/4.64/6.33亿元，首次覆盖给予“推荐”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.